Antiviral Treatment for Hepatitis C Cirrhosis: Is the Effort Justified?
Authors: Martin Black, Rebecca Thomas
Journal: Annals of Internal Medicine (2008)

Editorials16 September 2008Antiviral Treatment for Hepatitis C Cirrhosis: Is the Effort Justified?Martin Black, MD and Rebecca Thomas, MDMartin Black, MDFrom Temple University Hospital, Philadelphia, PA 19140.Search for more papers by this author and Rebecca Thomas, MDFrom Temple University Hospital, Philadelphia, PA 19140.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-6-200809160-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Cirrhosis resulting from chronic hepatitis C virus (HCV) infection occurs in 20% to 40% of infected individuals. Chronic HCV infection is the most common cause of cirrhosis in the United States (1) and is the most common diagnosis that leads to liver transplantation, and in many parts of the world, it is the leading disease associated with hepatocellular carcinoma (2). The prevalence of hepatitis C in the U.S. population has been estimated at 1.8% (3). This estimate, derived from NHANES III (Third National Health and Nutrition Examination Survey) data obtained from 1988 to 1994, is conservative; NHANES excluded incarcerated and ...References1. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513-21. [PMID: 17653645] CrossrefMedlineGoogle Scholar2. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2:1006-8. [PMID: 2572740] CrossrefMedlineGoogle Scholar3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62. [PMID: 10451460] CrossrefMedlineGoogle Scholar4. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141:715-7. [PMID: 15520428] LinkGoogle Scholar5. Chou R, Clark EC, Helfand M; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:465-79. [PMID: 15023713] LinkGoogle Scholar6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. [PMID: 11583749] CrossrefMedlineGoogle Scholar7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82. [PMID: 12324553] CrossrefMedlineGoogle Scholar8. Pleguezuelo M, Maselli L, Maimone S, Manousou P, Xirouchakis E, Burroughs AK. Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma? Curr Hepat Rep. 2008;7:72-80. CrossrefGoogle Scholar9. Fink S, Gaglio PJ. Hepatitis C in liver transplant patients. Curr Hepat Rep. 2008;7:81-7. CrossrefGoogle Scholar10. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatits C. Ann Intern Med. 2008;149:399-403. LinkGoogle Scholar11. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-84. [PMID: 18025443] LinkGoogle Scholar12. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117:1164-72. [PMID: 10535880] CrossrefMedlineGoogle Scholar13. Powell LW, Kerr JF. Reversal of “cirrhosis” in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med. 1970;19:54-7. [PMID: 5505522] CrossrefMedlineGoogle Scholar14. Falkmer S, Samuelson G, Sjölin S. Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics. 1970;45:260-8. [PMID: 5413388] MedlineGoogle Scholar15. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997;127:981-5. [PMID: 9412303] LinkGoogle Scholar16. Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med. 1997;126:682-8. [PMID: 9139553] LinkGoogle Scholar17. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-57. [PMID: 14647056] CrossrefMedlineGoogle Scholar18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5. [PMID: 7308988] CrossrefMedlineGoogle Scholar19. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15-20. [PMID: 8020885] CrossrefMedlineGoogle Scholar20. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655-69. [PMID: 18471545] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Martin Black, MD; Rebecca Thomas, MDAffiliations: From Temple University Hospital, Philadelphia, PA 19140.Disclosures: None disclosed.Corresponding Author: Martin Black, MD, Department of Medicine, Temple University Hospital, 3420 North Broad Street, Philadelphia, PA 19140; e-mail, martin.[email protected]temple.edu.Current Author Addresses: Drs. Black and Thomas: Department of Pathology and Laboratory Medicine, Temple University Hospital, 3420 North Broad Street, Philadelphia, PA 19140. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBrief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C Vincent Mallet , Hélène Gilgenkrantz , Jeanne Serpaggi , Virginie Verkarre , Anaïs Vallet-Pichard , Hélène Fontaine , and Stanislas Pol Metrics 16 September 2008Volume 149, Issue 6Page: 427-428KeywordsAutoimmune hepatitisCirrhosisFibrosisHepatitis CInterferonsLiverLiver diseasesLiver fibrosisPatientsPrimary biliary cirrhosis ePublished: 16 September 2008 Issue Published: 16 September 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...